Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119158 · ClinicalTrials.gov registry record · Phase 4
Combination Therapy for Atopic Dermatitis
A Phase 4 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT00119158 is a Phase 4 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 90 participants.
The verdict
NCT00119158, a Phase 4 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
Interventions
- DRUG Combination of pimecrolimus and fluticasone
- DRUG pimecrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119158
The ClinicalTrials.gov registry entry for NCT00119158 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Combination of pimecrolimus and fluticasone is the first listed.
NCT00119158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119158 about?
NCT00119158 is a clinical study titled "Combination Therapy for Atopic Dermatitis". Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and...
What is the current status of trial NCT00119158?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2004-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00119158?
The interventions under investigation include: Combination of pimecrolimus and fluticasone (DRUG), pimecrolimus (DRUG).
Who is sponsoring clinical trial NCT00119158?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.